Scott & Selber Inc’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-30,276
Closed -$876K 94
2024
Q3
$876K Sell
30,276
-343
-1% -$10K 0.27% 77
2024
Q2
$857K Buy
30,619
+212
+0.7% +$5.84K 0.27% 77
2024
Q1
$844K Sell
30,407
-375
-1% -$10.4K 0.29% 78
2023
Q4
$886K Sell
30,782
-150
-0.5% -$4.53K 0.33% 81
2023
Q3
$1.03M Sell
30,932
-438
-1% -$15.5K 0.42% 71
2023
Q2
$1.15M Sell
31,370
-237
-0.7% -$9.22K 0.45% 68
2023
Q1
$1.29M Hold
31,607
0.55% 62
2022
Q4
$1.62M Sell
31,607
-56
-0.2% -$2.69K 0.73% 53
2022
Q3
$1.39M Buy
31,663
+145
+0.5% +$7.05K 0.67% 57
2022
Q2
$1.65M Sell
31,518
-600
-2% -$30.6K 0.75% 51
2022
Q1
$1.66M Sell
32,118
-7,990
-20% -$415K 0.64% 60
2021
Q4
$2.37M Buy
40,108
+7,449
+23% +$369K 0.84% 43
2021
Q3
$1.41M Sell
32,659
-1,271
-4% -$56.3K 0.57% 68
2021
Q2
$1.33M Sell
33,930
-261
-0.8% -$10.2K 0.51% 73
2021
Q1
$1.24M Sell
34,191
-1,588
-4% -$56.4K 0.51% 70
2020
Q4
$1.32M Sell
35,779
-6,544
-15% -$240K 0.56% 68
2020
Q3
$1.47M Buy
42,323
+1,242
+3% +$43.5K 0.66% 64
2020
Q2
$1.27M Buy
+41,081
New +$1.4M 0.63% 67

Other funds holding PFE

Scott & Selber Inc's PFE Position: Q4 2024 in Review

Scott & Selber Inc sold out of Pfizer (PFE) in Q4 2024, closing a stake of 30,276 shares — an estimated $876K sold.

Scott & Selber Inc first reported a position in PFE in Q2 2020 and held it in 18 quarters. The position peaked at $2.37M in Q4 2021. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Scott & Selber Inc reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
  • Scott & Selber Inc sold 30,276 Pfizer shares in Q4 2024, an estimated $876K.
  • Scott & Selber Inc first reported a position in Pfizer in Q2 2020 and held it in 18 quarters.
  • Scott & Selber Inc's Pfizer position peaked at $2.37M in Q4 2021.
  • 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Scott & Selber Inc's 13F filing for Q4 2024, filed 6 Feb 2025.